318 related articles for article (PubMed ID: 29725371)
1. Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease.
Zhang J; Hu J; Zhang C; Jiao Y; Kong X; Wang W
Exp Ther Med; 2018 May; 15(5):4259-4264. PubMed ID: 29725371
[TBL] [Abstract][Full Text] [Related]
2. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease].
Chen Y; Wang XJ; Jin HL; Jin L
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
4. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
5. Metabolic disparities between obese and non-obese patients with polycystic ovary syndrome: implications for endometrial receptivity indicators.
Li XL; Ji YF; Feng Y; Liu SW
Gynecol Endocrinol; 2024 Dec; 40(1):2312895. PubMed ID: 38444321
[TBL] [Abstract][Full Text] [Related]
6. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.
Wang D; Nan N; Bing H; He B
Front Endocrinol (Lausanne); 2023; 14():1241734. PubMed ID: 37720537
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
[TBL] [Abstract][Full Text] [Related]
8. Serum uric acid/creatinine ratio and free androgen index are synergistically associated with increased risk of polycystic ovary syndrome in obese women.
El-Eshmawy MM; Ibrahim A; Bahriz R; Shams-Eldin N; Mahsoub N
BMC Endocr Disord; 2022 Dec; 22(1):315. PubMed ID: 36514085
[TBL] [Abstract][Full Text] [Related]
9. Sex Hormone-Binding Globulin (SHBG) Reduction: The Alarm Bell for the Risk of Non-Alcoholic Fatty Liver Disease in Adolescents with Polycystic Ovary Syndrome.
Urbano F; Chiarito M; Lattanzio C; Messa A; Ferrante M; Francavilla M; Mehmeti I; Lassandro G; Giordano P; Faienza MF
Children (Basel); 2022 Nov; 9(11):. PubMed ID: 36421197
[TBL] [Abstract][Full Text] [Related]
10. Expression of Serum Omentin, CTRP9, and Vaspin in Patients with Polycystic Ovary Syndrome.
Wang Y; Liu N; Lu J; Yang L; Wang C; Chen J; Chang W
Evid Based Complement Alternat Med; 2022; 2022():1862404. PubMed ID: 36034953
[TBL] [Abstract][Full Text] [Related]
11. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
Holte J; Bergh T; Gennarelli G; Wide L
Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
[TBL] [Abstract][Full Text] [Related]
12. [Study on the correlation between different Chinese medicine syndrome types and endocrine metabolism of polycystic ovarian syndrome].
Wang XJ; Zeng XL; Liu Y
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Aug; 31(8):1085-9. PubMed ID: 21910340
[TBL] [Abstract][Full Text] [Related]
13. [Acupuncture Treatment of Polycystic Ovarian Syndrome Patients with Abdominal Obesity by Regulating Dai Meridian: A Randomized Controlled Clinical Trial].
Shen LY; Liang CM; Yang WJ; Pan L; Li H; Hu H
Zhen Ci Yan Jiu; 2018 Apr; 43(4):255-9. PubMed ID: 29888581
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome].
Liu ZA; Xue YM; Chen LX; Cai Q; Chen H; Zhang J; Cui QH; Ge J; Yuan T
Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):586-90. PubMed ID: 15498183
[TBL] [Abstract][Full Text] [Related]
15. High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance.
Cai J; Wu CH; Zhang Y; Wang YY; Xu WD; Lin TC; Li SX; Wang LH; Zheng J; Sun Y; Liu W; Tao T
Int J Obes (Lond); 2017 Sep; 41(9):1341-1347. PubMed ID: 28487551
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Androgen Levels, Endocrine and Metabolic Indices, and Clinical Findings in Women with Polycystic Ovary Syndrome in Uygur and Han Ethnic Groups from Xinjiang Province in China.
Zhao H; Song X; Zhang L; Xu Y; Wang X
Med Sci Monit; 2018 Sep; 24():6774-6780. PubMed ID: 30252834
[TBL] [Abstract][Full Text] [Related]
17. [Effect of abdominal acupuncture therapy on the endocrine and metabolism in obesity-type polycystic ovarian syndrome patients].
Lai MH; Ma HX; Yao H; Liu H; Song XH; Huang WY; Wu XK
Zhen Ci Yan Jiu; 2010 Aug; 35(4):298-302. PubMed ID: 21090334
[TBL] [Abstract][Full Text] [Related]
18. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
Singh S; Akhtar N; Ahmad J
Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
[TBL] [Abstract][Full Text] [Related]
19. Exploring the significance of sex hormone-binding globulin examination in the treament of women with polycystic ovarian syndrome (PCOS).
Lin XF; Wu RR; Du J; Liao YC; Du Y; Ye Y; Wang Y; Zhang XB; Wu C; Chen A
Clin Exp Obstet Gynecol; 2015; 42(3):315-20. PubMed ID: 26152001
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome - clinical and metabolic aspects and lipoprotein lipase gene polymorphism.
Bohdanowicz-Pawlak A; Lenarcik-Kabza A; Brona A; Kuliczkowska-Płaksej J; Łaczmański Ł; Zaleska-Dorobisz U; Milewicz A
Endokrynol Pol; 2014; 65(6):416-21. PubMed ID: 25554608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
